DK2381969T3 - Fremgangsmåder til fremstilling af sårbandager og en bank af sårbandager - Google Patents
Fremgangsmåder til fremstilling af sårbandager og en bank af sårbandager Download PDFInfo
- Publication number
- DK2381969T3 DK2381969T3 DK10705443.9T DK10705443T DK2381969T3 DK 2381969 T3 DK2381969 T3 DK 2381969T3 DK 10705443 T DK10705443 T DK 10705443T DK 2381969 T3 DK2381969 T3 DK 2381969T3
- Authority
- DK
- Denmark
- Prior art keywords
- blood
- clot
- whole blood
- wound
- dressing
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 76
- 210000004369 blood Anatomy 0.000 claims description 222
- 239000008280 blood Substances 0.000 claims description 221
- 230000015271 coagulation Effects 0.000 claims description 17
- 238000005345 coagulation Methods 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 230000007480 spreading Effects 0.000 claims description 16
- 238000003892 spreading Methods 0.000 claims description 16
- 238000005520 cutting process Methods 0.000 claims description 10
- 239000003999 initiator Substances 0.000 claims description 8
- 230000001112 coagulating effect Effects 0.000 claims description 2
- 230000014508 negative regulation of coagulation Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 description 135
- 206010052428 Wound Diseases 0.000 description 134
- 238000011282 treatment Methods 0.000 description 54
- 239000010410 layer Substances 0.000 description 47
- 230000035602 clotting Effects 0.000 description 44
- 210000003491 skin Anatomy 0.000 description 43
- 239000003146 anticoagulant agent Substances 0.000 description 40
- 229940127219 anticoagulant drug Drugs 0.000 description 40
- 206010053567 Coagulopathies Diseases 0.000 description 33
- 239000000463 material Substances 0.000 description 23
- 208000007536 Thrombosis Diseases 0.000 description 21
- 238000010586 diagram Methods 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 208000025865 Ulcer Diseases 0.000 description 16
- 230000036512 infertility Effects 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 239000000306 component Substances 0.000 description 14
- 230000035876 healing Effects 0.000 description 14
- 238000003860 storage Methods 0.000 description 14
- 231100000397 ulcer Toxicity 0.000 description 14
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 13
- 230000001684 chronic effect Effects 0.000 description 13
- 229920000742 Cotton Polymers 0.000 description 12
- 108010073385 Fibrin Proteins 0.000 description 12
- 102000009123 Fibrin Human genes 0.000 description 12
- 229950003499 fibrin Drugs 0.000 description 12
- 230000002745 absorbent Effects 0.000 description 10
- 239000002250 absorbent Substances 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000005995 Aluminium silicate Substances 0.000 description 8
- 235000012211 aluminium silicate Nutrition 0.000 description 8
- 239000004227 calcium gluconate Substances 0.000 description 8
- 229960004494 calcium gluconate Drugs 0.000 description 8
- 235000013927 calcium gluconate Nutrition 0.000 description 8
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000000416 exudates and transudate Anatomy 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 6
- 208000028990 Skin injury Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000034693 Laceration Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 206010016717 Fistula Diseases 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000003890 fistula Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010011985 Decubitus ulcer Diseases 0.000 description 3
- 108010071289 Factor XIII Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 229920006298 saran Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- -1 antiseptics Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- HYNPZTKLUNHGPM-KKERQHFVSA-N becaplermin Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](Cc8c[nH]c9c8cccc9)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)N HYNPZTKLUNHGPM-KKERQHFVSA-N 0.000 description 1
- 229960004787 becaplermin Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- UGZVNIRNPPEDHM-SBBOJQDXSA-L calcium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioate Chemical compound [Ca+2].[O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O UGZVNIRNPPEDHM-SBBOJQDXSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940033618 tisseel Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/16—Holders for containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials For Medical Uses (AREA)
Claims (7)
- FREMGANGSMÅDER TIL FREMSTILLING AF SÅRBANDAGER OG EN BANK AF SÅRBANDAGER1. Fremgangsmåde til fremstilling af en sårbandage, hvilken fremgangsmåde omfatter: (a) tilvejebringelse af et volumen af indsamlet fuldblod; (b) koagulering af fuldblodet for at danne et koagel ex vivo og (c) dannelse af en sårbandage omfattende koagelet.
- 2. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde omfatter skæring af en del af koagelet i dimensioner, der er egnede til at bandagering af et specifikt sår.
- 3. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde omfatter tilvejebringelse af en støttestruktur, hvorpå koagelet dannes.
- 4. Fremgangsmåde til fremstilling af en biologisk sårbandage, hvilken fremgangsmåde omfatter, (a) spredning af en enhed af fuldblod på et væv til at dække et område og (b) at lade fuldblodet koagulere for derved at danne et koaguleret blodlag med vævet indlejret i koagelet.
- 5. Fremgangsmåde ifølge krav 4, hvilken fremgangsmåde omfatter tilsætning af en koagulationsinitiator før spredningen.
- 6. Fremgangsmåde ifølge krav 5, hvor koagulationsinitiatoren er udvalgt til at neutralisere en aktivitet af et antikoagulant i enheden.
- 7. Bank af biologiske sårbandager, hvilken bank omfatter: en flerhed af sterile lage af koaguleret fuldblod og krydskompatibilitetsinformationer for hvert aflagene.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14751309P | 2009-01-27 | 2009-01-27 | |
| PCT/IL2010/000066 WO2010086848A2 (en) | 2009-01-27 | 2010-01-27 | Wound dressings, methods and apparatus for making same and storage and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2381969T3 true DK2381969T3 (da) | 2016-09-05 |
Family
ID=42269321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10705443.9T DK2381969T3 (da) | 2009-01-27 | 2010-01-27 | Fremgangsmåder til fremstilling af sårbandager og en bank af sårbandager |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20110318404A1 (da) |
| EP (1) | EP2381969B1 (da) |
| JP (3) | JP6134933B2 (da) |
| KR (2) | KR101877694B1 (da) |
| CN (2) | CN102341130B (da) |
| AU (1) | AU2010209342B2 (da) |
| BR (1) | BRPI1005362B1 (da) |
| CA (1) | CA2750779C (da) |
| DK (1) | DK2381969T3 (da) |
| ES (1) | ES2587380T3 (da) |
| PL (1) | PL2381969T3 (da) |
| WO (1) | WO2010086848A2 (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2381969T3 (da) | 2009-01-27 | 2016-09-05 | Reddress Ltd | Fremgangsmåder til fremstilling af sårbandager og en bank af sårbandager |
| US10088397B2 (en) * | 2013-06-19 | 2018-10-02 | Advance Dx, Inc. | Fluid separator collection card assembly |
| US12357469B2 (en) * | 2014-11-16 | 2025-07-15 | Spinesmith Partners, L.P. | System and method of treatment of bone lesions |
| US10213461B2 (en) | 2015-08-24 | 2019-02-26 | Arthrex, Inc | Combined autologous biologic and cold therapy treatment of skin injuries |
| US20170056450A1 (en) * | 2015-08-24 | 2017-03-02 | Arthrex, Inc. | Combined autologous biologic and cold therapy treatment of skin injuries |
| CA3024511A1 (en) * | 2016-05-31 | 2017-12-07 | Octapharma Ag | Plasma-based films and methods for making and using the same |
| SE540816C2 (en) | 2017-07-17 | 2018-11-20 | Ortrud Medical Ab | Tourniquet |
| IL254644B (en) * | 2017-09-24 | 2021-06-30 | Reddress Ltd | Device for dressing a wound, system and method |
| IL254636A0 (en) * | 2017-09-24 | 2017-11-30 | Reddress Ltd | System and method for preparing a wound dressing |
| IL257229B (en) * | 2018-01-30 | 2022-07-01 | Reddress Ltd | Blood applicator for tissue treatment |
| CN112469375B (zh) * | 2018-06-15 | 2022-09-06 | 科洛普拉斯特公司 | 伤口敷料系统的附属装置、以及用于传达操作状态的相关方法 |
| CN110237094B (zh) * | 2019-07-30 | 2023-10-03 | 天晴干细胞股份有限公司 | 一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法 |
| EP3789052A1 (en) * | 2019-09-03 | 2021-03-10 | Smith & Nephew, Inc. | Fibrin clot preparation instruments and method |
| WO2021124317A1 (en) | 2019-12-17 | 2021-06-24 | Reddress Ltd. | Assembly and method for the preparation of a wound dressing |
| IL273876B2 (en) * | 2020-04-07 | 2024-02-01 | Reddress Ltd | A method and system for creating a coagulated blood-based dressing, and a connection device that enables this |
| US20230172758A1 (en) * | 2020-05-26 | 2023-06-08 | Gregory O'Keeffe | Augmented wound dressing systems and methods for using same and systems, devices, and methods for monitoring the healing process of wounds |
| JP2024509696A (ja) | 2021-02-08 | 2024-03-05 | レッドドレス リミテッド | 異常な空洞空間を治療するための方法及びキット |
| IL281044B (en) | 2021-02-23 | 2022-04-01 | Reddress Ltd | Method and kit for treating damaged nerves |
| IL286333B2 (en) | 2021-09-13 | 2023-04-01 | Reddress Ltd | Device and method for treating vaginal tissue |
| IL289281B2 (en) | 2021-12-22 | 2023-06-01 | Reddress Ltd | Method and kit for the treatment of damaged connective tissues |
| IL290122B2 (en) * | 2022-01-25 | 2023-08-01 | Reddress Ltd | Clotting template, kit and method for making a blood clot |
| IL292189B2 (en) | 2022-04-12 | 2023-09-01 | Reddress Ltd | A coagulation mold and its manufacturing process |
| IL296102A (en) | 2022-08-31 | 2024-03-01 | Reddress Ltd | Method and System for Treatment of Bone or Joint |
| IL297401A (en) | 2022-10-18 | 2024-05-01 | Reddress Ltd | Elements and system for treating wounds |
| IL300830B2 (en) | 2023-02-21 | 2024-08-01 | Reddress Ltd | The implantable device coated with clotted blood |
| IL301095A (en) | 2023-03-02 | 2024-10-01 | Reddress Ltd | Method and kit combining a support matrix and a coagulating blood mass |
| WO2025243291A1 (en) | 2024-05-19 | 2025-11-27 | Reddress Ltd. | Method and kit for treating a wound |
| WO2025243305A1 (en) | 2024-05-23 | 2025-11-27 | Reddress Ltd. | Controlled drug delivery |
| EP4686486A1 (en) | 2024-07-30 | 2026-02-04 | Paul Hartmann AG | Gel composition comprising whole blood |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB891963A (en) * | 1957-04-08 | 1962-03-21 | Clifford Reginald Watts | Surgical dressing packages |
| US3723244A (en) | 1971-01-18 | 1973-03-27 | Atomic Energy Commission | Fibrous fibrin sheet and method for producing same |
| US4035483A (en) * | 1973-05-29 | 1977-07-12 | John Bunyan | Antiseptic and non-toxic substance and a method of making the same |
| US4347841A (en) | 1981-03-11 | 1982-09-07 | Human Oltoanyagtermelo Es Kutato Intezet | Biological wound covering and method for producing same |
| EP0265906B1 (en) * | 1986-10-31 | 1995-04-19 | Nippon Zeon Co., Ltd. | Wound dressing |
| IT1230059B (it) * | 1989-04-17 | 1991-09-27 | Dorin Olimpiu Petrescu | Procedimento per la preparazione in vitro di membrane emostatiche artificiali. |
| US5610148A (en) | 1991-01-18 | 1997-03-11 | University College London | Macroscopically oriented cell adhesion protein for wound treatment |
| US5629287A (en) | 1991-01-18 | 1997-05-13 | University College London | Depot formulations |
| JPH05234916A (ja) | 1992-02-20 | 1993-09-10 | Nippon Steel Corp | 分子線エピタキシー装置 |
| JP3466815B2 (ja) * | 1996-03-29 | 2003-11-17 | オーソ・クリニカル・ダイアグノスティックス株式会社 | 輸血検査解析システムおよび輸血検査解析の方法 |
| WO1998012274A1 (en) * | 1996-09-23 | 1998-03-26 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
| US6060461A (en) | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
| WO2001021195A1 (en) | 1999-09-24 | 2001-03-29 | Univ Virginia | Composition and method for treating burns |
| US6521265B1 (en) | 2000-02-09 | 2003-02-18 | Biolife, L.L.C. | Method for applying a blood clotting agent |
| US20040147024A1 (en) | 2000-02-10 | 2004-07-29 | Crowe John H. | Therapeutic platelets and methods |
| US8229675B2 (en) * | 2000-03-31 | 2012-07-24 | Global Med Technologies, Inc. | Patient information bar and method for tracking and displaying blood products |
| GB2365443B (en) | 2000-04-04 | 2004-12-22 | Denis Eon Solomon | A surgical-medical dressing for the treatment of body burns and for wound healing |
| AU2001257397B2 (en) * | 2000-04-28 | 2005-08-04 | Biolife, L.L.C | Hemostatic agent, method and carrier for applying a blood clotting agent |
| ES2173812B1 (es) | 2001-03-01 | 2003-12-16 | Ct Investig Energeticas Ciemat | Dermis artificial y metodo de obtencion. |
| US20040124564A1 (en) | 2002-12-30 | 2004-07-01 | Noorjahan Sheik Eusuff | Process for preparing a chemically modified fibrin-fibrillar protein (FFP) composite sheet |
| JP2004339496A (ja) * | 2003-04-21 | 2004-12-02 | Hiroshi Takimoto | 生分解性組成物及びそれを用いた基材 |
| TW200505394A (en) * | 2003-06-06 | 2005-02-16 | Asahi Medical Co | Material promoting wound healing |
| US20070077610A1 (en) * | 2005-09-30 | 2007-04-05 | Jyotsna Ghai | Membrane system for blood coagulation testing |
| US7604819B2 (en) * | 2006-05-26 | 2009-10-20 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
| US7968114B2 (en) * | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
| JP5234916B2 (ja) | 2007-01-30 | 2013-07-10 | 東レ株式会社 | 積層研磨パッド |
| US20090011043A1 (en) | 2007-07-03 | 2009-01-08 | Hua Xie | Tissue sealant made from whole blood |
| DK2381969T3 (da) | 2009-01-27 | 2016-09-05 | Reddress Ltd | Fremgangsmåder til fremstilling af sårbandager og en bank af sårbandager |
-
2010
- 2010-01-27 DK DK10705443.9T patent/DK2381969T3/da active
- 2010-01-27 KR KR1020177012187A patent/KR101877694B1/ko active Active
- 2010-01-27 US US13/145,205 patent/US20110318404A1/en not_active Abandoned
- 2010-01-27 BR BRPI1005362A patent/BRPI1005362B1/pt active IP Right Grant
- 2010-01-27 KR KR1020117019952A patent/KR101734815B1/ko active Active
- 2010-01-27 JP JP2011547055A patent/JP6134933B2/ja active Active
- 2010-01-27 CN CN201080009823.0A patent/CN102341130B/zh active Active
- 2010-01-27 ES ES10705443.9T patent/ES2587380T3/es active Active
- 2010-01-27 CA CA2750779A patent/CA2750779C/en active Active
- 2010-01-27 CN CN201710989983.XA patent/CN107854717B/zh active Active
- 2010-01-27 WO PCT/IL2010/000066 patent/WO2010086848A2/en not_active Ceased
- 2010-01-27 PL PL10705443.9T patent/PL2381969T3/pl unknown
- 2010-01-27 AU AU2010209342A patent/AU2010209342B2/en active Active
- 2010-01-27 EP EP10705443.9A patent/EP2381969B1/en active Active
-
2014
- 2014-04-08 US US14/247,725 patent/US9180142B2/en active Active
-
2015
- 2015-06-01 JP JP2015111138A patent/JP2015221212A/ja not_active Ceased
- 2015-11-05 US US14/933,178 patent/US10111979B2/en active Active
-
2017
- 2017-02-16 JP JP2017026664A patent/JP6419872B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2381969A2 (en) | 2011-11-02 |
| CN102341130B (zh) | 2017-11-10 |
| AU2010209342B2 (en) | 2014-12-04 |
| KR20110113754A (ko) | 2011-10-18 |
| JP2012515602A (ja) | 2012-07-12 |
| JP6134933B2 (ja) | 2017-05-31 |
| EP2381969B1 (en) | 2016-05-18 |
| WO2010086848A3 (en) | 2011-01-06 |
| CA2750779C (en) | 2016-11-08 |
| CN107854717B (zh) | 2021-06-01 |
| US20160256593A1 (en) | 2016-09-08 |
| US20110318404A1 (en) | 2011-12-29 |
| KR101877694B1 (ko) | 2018-07-11 |
| HK1252027A1 (zh) | 2019-05-10 |
| ES2587380T3 (es) | 2016-10-24 |
| BRPI1005362A2 (pt) | 2016-12-13 |
| PL2381969T3 (pl) | 2016-12-30 |
| CA2750779A1 (en) | 2010-08-05 |
| BRPI1005362B1 (pt) | 2019-01-29 |
| AU2010209342A1 (en) | 2011-08-11 |
| US9180142B2 (en) | 2015-11-10 |
| CN107854717A (zh) | 2018-03-30 |
| US20150044272A1 (en) | 2015-02-12 |
| US10111979B2 (en) | 2018-10-30 |
| CN102341130A (zh) | 2012-02-01 |
| KR20170056705A (ko) | 2017-05-23 |
| JP2015221212A (ja) | 2015-12-10 |
| JP6419872B2 (ja) | 2018-11-07 |
| JP2017104602A (ja) | 2017-06-15 |
| KR101734815B1 (ko) | 2017-05-12 |
| WO2010086848A2 (en) | 2010-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2381969T3 (da) | Fremgangsmåder til fremstilling af sårbandager og en bank af sårbandager | |
| JP6892485B2 (ja) | トロンビン血清の調製、その利用およびその調製機器 | |
| US6762336B1 (en) | Hemostatic sandwich bandage | |
| JP2010115504A (ja) | 止血サンドウィッチ包帯 | |
| Abdullah et al. | Evaluate the effects of platelet rich plasma (PRP) and zinc oxide ointment on skin wound healing | |
| KR20170102319A (ko) | 혈소판을 분리하는 방법 | |
| JP5766439B2 (ja) | 止血および創傷治癒を促進するためのスクリーンへのポリマー材料の適用 | |
| RU2548741C2 (ru) | Активированная лейкоцитарная композиция | |
| Altmeyer et al. | Wound healing and skin physiology | |
| US20150352151A1 (en) | Activated leukocyte composition and uses for wound healing | |
| Cahn et al. | Cellular-and acellular-based therapies: skin substitutes and matrices | |
| CN108434529A (zh) | 一种脂肪液化伤口用原位自体仿生修复材料及其制备方法和应用 | |
| HK1252027B (zh) | 创伤敷料、用於制造创伤敷料的方法和设备以及其储存和用途 | |
| RU2354406C1 (ru) | Гемостатический материал | |
| Läuchli et al. | Leg Ulcers | |
| Alvarez et al. | Local care of diabetic foot ulcers: Assessment, dressings, and topical treatments | |
| Assessment | Local Care of Diabetic Foot Ulcers |